Silo Pharma Inc. (NASDAQ: SILO) issued a statement regarding recent federal actions aimed at advancing psychedelic-based therapeutics for mental health and substance use disorders. The company said these initiatives validate its approach to treating neurological and psychiatric conditions.

The Advanced Research Projects Agency for Health announced initial awardees under its EVIDENT program, including Johns Hopkins University and other institutions focused on psychedelic science. The Food and Drug Administration granted investigational new drug clearance to DemeRx NB for its noribogaine candidate targeting alcohol use disorder.

The FDA issued three Commissioner's National Priority Vouchers to Compass Pathways, Usona Institute, and Transcend Therapeutics. The agency confirmed that final guidance for psychedelic drug development will be published soon.

"We are witnessing a coordinated and accelerating shift at the federal level," said Silo CEO Eric Weisblum. "From funding and clinical advancement to regulatory prioritization, in our opinion the foundation is being laid for a new generation of therapies that could transform how we treat PTSD and related disorders."

Silo Pharma describes itself as a developmental-stage biopharmaceutical company focused on underserved conditions including stress-induced psychiatric disorders, chronic pain, and central nervous system diseases. The company's portfolio includes SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer's disease.

The information is based on a company press release statement.